½ÃÀ庸°í¼­
»óǰÄÚµå
1305236

¼¼°èÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)

Global Acute Respiratory Distress Syndrome Devices Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2022³â 3¾ï 1,432¸¸ ´Þ·¯¿¡¼­ 2030³â 6¾ï 6,986¸¸ ´Þ·¯¿¡ À°¹ÚÇÏ´Â ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2023-2030³â Á¶»ç ±â°£ µ¿¾È 9.92%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS)Àº Æó·Å, ÆÐÇ÷Áõ, ¿Ü»ó, ÈíÀÔ ¼Õ»ó µî ¿©·¯ °¡Áö º´Àû »óÅ¿¡ ¹ÝÀÀÇÏ¿© ¹ß»ýÇÏ´Â ½É°¢ÇÑ È£Èí±â ÁúȯÀ¸·Î, ÆóÀÇ ¿°ÁõÀÌ Æ¯Â¡À̸ç, ü¾× Àú·ù¿Í È£Èí °ï¶õÀ» À¯¹ßÇÕ´Ï´Ù. ARDS ȯÀÚÀÇ È£ÈíÀ» º¸´Ù ½±°í È¿°úÀûÀ¸·Î µ½±â À§ÇØ ARDS Ä¡·á Àåºñ°¡ »ç¿ëµÇ¸ç, ±â°è½Ä ÀΰøÈ£Èí±â, ü¿Ü¸· »ê¼ÒÈ­(ECMO) ÀåÄ¡, °í À¯·® ºñ°­ ij´¼¶ó ½Ã½ºÅÛ µî ARDS Ä¡·á Àåºñ´Â »ý¸íÀ» À§ÇùÇÒ ¼ö ÀÖ½À´Ï´Ù. ARDS´Â »ý¸íÀ» À§ÇùÇÏ´Â ÁúȯÀ̱⠶§¹®¿¡ ARDS Ä¡·á Àåºñ´Â ARDS ȯÀÚ Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â »ê¼Ò °ø±ÞÀ» °³¼±ÇÏ°í ÆóÀÇ ºÎ´ãÀ» ÁÙ¿© ȯÀÚ°¡ ARDS¸¦ À¯¹ßÇÑ ±âÀú ÁúȯÀ¸·ÎºÎÅÍ È¸º¹ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

ARDSÀÇ ¹ß»ý·üÀº Àα¸ °í·ÉÈ­, ¸¸¼º ÁúȯÀÇ Áõ°¡, ÆÐÇ÷Áõ ¹× Æó·Å ¹ß»ý·ü Áõ°¡¿Í °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ »óÅÂÀÇ È¯ÀÚ¿¡°Ô È£Èí Áö¿øÀ» Á¦°øÇÏ´Â ARDS ÀåÄ¡¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â°è½Ä ÀΰøÈ£Èí±â ¹× ¿¡Å©¸ð ÀåÄ¡¿Í °°Àº È£Èí º¸Á¶ ÀåÄ¡ÀÇ ±â¼ú ¹ßÀüÀº ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ È¿À²¼º°ú È¿°ú¸¦ Çâ»ó½ÃÄÑ ARDS ÀåÄ¡ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿ë·® Á¦¾î ȯ±â ¹× ¾Ð·Â Á¦¾î ȯ±â¿Í °°Àº »õ·Î¿î ȯ±â ¸ðµå´Â È£Èí º¸Á¶¸¦º¸´Ù Á¤È®ÇÏ°Ô Á¦¾î ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ³ëÀÎ Àα¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ³ëÀεéÀº ARDS¿Í °°Àº È£Èí±â Áúȯ¿¡ °É¸®±â ½±±â ¶§¹®¿¡ ARDS Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸´Â ARDS ÀåÄ¡¸¦ »ç¿ëÇØ¾ß ÇÒ ¼ö ÀÖ´Â ´Ù¸¥ µ¿¹Ý ÁúȯÀ» ¾Î°í ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Àü ¼¼°è °¢±¹ Á¤ºÎ´Â ARDS ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ÀÇÇÐ ¿¬±¸, ÀÓ»ó½ÃÇè ¹× ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ƯÈ÷ COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ±â°è½Ä ÀΰøÈ£Èí±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖÀ¸¸ç, COVID-19ÀÇ ÁßÁõ »ç·Ê´Â ARDS·Î À̾îÁú ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±Þ¼º È£Èí °ï¶õ ÁõÈıº ÀåÄ¡ »ê¾÷ÀÇ ¼ºÀå°ú Ãß¼¼´ÂÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­:

±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡°¡ ÇâÈÄ ±âȸ¿Í ÇÔ²² °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

À¯Çüº°

  • Ä¡·á ÀåÄ¡(±â°è½Ä ÀΰøÈ£Èí±â, PAP, ±âŸ)
  • Áø´Ü ¹× ¸ð´ÏÅ͸µ Àåºñ

ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Àü¹®¼¾ÅÍ
  • ±âŸ

Áö¿ªº° ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • »ê¾÷ µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ¼¼°è ½ÃÀå ºÐ¼® : À¯Çüº°

  • À¯Çüº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • À¯Çüº° ºÐ¼®
  • Ä¡·á µð¹ÙÀ̽º(±â°è½Ä ÀΰøÈ£Èí±â, PAP, ±âŸ)
  • Áø´Ü¡¤¸ð´ÏÅ͸µ ±â±â

Á¦7Àå ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
  • º´¿ø
  • Àü¹® ¼¾ÅÍ
  • ±âŸ

Á¦8Àå ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ±â¾÷ °æÀï »óȲ

  • ±Þ¼º È£Èí°ï¶õ ÁõÈıº ±â±â ½ÃÀå °æÀï
  • Á¦ÈÞ/Çù·Â/ÇÕÀÇ
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • koninklijke Plilips N.V
  • Medtronic
  • Fisher & Paykel Healthcare Limited.
  • Dragerwerk AG & Co. KGaA
  • Smiths Medical(ICU Medical Inc.)
  • Hamilton Medical
  • GE Healthcare
  • ResMed
  • Getinge AB
  • Other

Âü°í - ±â¾÷ °³¿ä¿¡¼­ À繫 »ó¼¼³ª ÃÖ±ÙÀÇ µ¿ÇâÀº ºñ°ø°³ ±â¾÷ÀÇ °æ¿ì ÀÔ¼ö °¡´É ¿©ºÎ¿¡ µû¶ó ´Þ¶óÁö°Å³ª Á¦°øµÇÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

ksm 23.08.22

The global demand for Acute Respiratory Distress Syndrome Devices Market is presumed to reach the market size of nearly USD 669.86 MN by 2030 from USD 314.32 MN in 2022 with a CAGR of 9.92% under the study period 2023 - 2030.

Acute Respiratory Distress Syndrome (ARDS) devices refer to medical devices and equipment used to provide respiratory support to patients suffering from ARDS. ARDS is a severe respiratory condition that can occur in response to various medical conditions, such as pneumonia, sepsis, trauma, or inhalation injury. It is characterized by inflammation in the lungs that can lead to fluid accumulation and difficulty breathing. ARDS devices are used to help patients with ARDS breathe more easily and effectively. Some examples of ARDS devices include mechanical ventilators, extracorporeal membrane oxygenation (ECMO) machines, and high-flow nasal cannula systems. ARDS devices are critical in the treatment of patients with ARDS, as the condition can be life-threatening. These devices can help improve oxygenation and reduce the workload on the lungs, allowing the patient to recover from the underlying condition that led to ARDS.

Market Dynamics:

The incidence of ARDS is increasing due to factors such as ageing populations, increasing rates of chronic diseases, and higher rates of sepsis and pneumonia leading to growing need for ARDS devices to provide respiratory support for patients with this condition. Technological advancements in respiratory support devices, such as mechanical ventilators and ECMO machines, have improved the efficiency and effectiveness of these devices, driving the growth of the ARDS devices market. For example, new ventilation modes, such as volume-controlled ventilation and pressure-controlled ventilation, can provide more precise control of respiratory support. The geriatric population is growing globally, leading to an increased demand for ARDS devices as older adults are more susceptible to respiratory conditions such as ARDS. Additionally, the geriatric population often has other comorbidities that may require the use of ARDS devices. Governments around the world are investing in medical research, clinical trials and initiatives aimed at improving outcomes for patients with ARDS. The COVID-19 pandemic has led to a ARDS devices surge in demand for, particularly mechanical ventilators, as severe cases of COVID-19 can lead to ARDS.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of acute respiratory distress syndrome devices. The growth and trends of acute respiratory distress syndrome devices industry provide a holistic approach to this study.

Market Segmentation:

This section of the acute respiratory distress syndrome devices market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Therapeutic Devices (Mechanical Ventilators, PAP, Others)
  • Diagnostic & Monitoring Devices

By End User

  • Hospitals
  • Specialty Centers
  • Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Acute Respiratory Distress Syndrome Devices market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the acute respiratory distress syndrome devices market include koninklijke Plilips N.V, Medtronic, Fisher & Paykel Healthcare Limited., Dragerwerk AG & Co. KGaA, Smiths Medical (ICU Medical, Inc.), Hamilton Medical, GE Healthcare, ResMed, Getinge AB, Other. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ACUTE RESPIRATORY DISTRESS SYNDROME DEVICES - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By End User
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME DEVICES MARKET ANALYSIS BY TYPE

  • 6.1 Overview by Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Type
  • 6.4 Therapeutic Devices (Mechanical Ventilators, PAP, Others) Historic and Forecast Sales by Regions
  • 6.5 Diagnostic & Monitoring Devices Historic and Forecast Sales by Regions

7 . GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME DEVICES MARKET ANALYSIS BY END USER

  • 7.1 Overview by End User
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End User
  • 7.4 Hospitals Historic and Forecast Sales by Regions
  • 7.5 Specialty Centers Historic and Forecast Sales by Regions
  • 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME DEVICES MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ACUTE RESPIRATORY DISTRESS SYNDROME DEVICES COMPANIES

  • 9.1. Acute Respiratory Distress Syndrome Devices Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF ACUTE RESPIRATORY DISTRESS SYNDROME DEVICES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. koninklijke Plilips N.V
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Medtronic
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Fisher & Paykel Healthcare Limited.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Dragerwerk AG & Co. KGaA
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Smiths Medical (ICU Medical Inc.)
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Hamilton Medical
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. GE Healthcare
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. ResMed
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Getinge AB
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Other
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦